{"url_path":"/sec/tndm/8-k/2026-05-21/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000070-index.html","accession_number":"0001438133-26-000070","cik":"0001438133","ticker":"TNDM","issuer_name":"TANDEM DIABETES CARE INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000070-index.html","primary_entity_key":"0001438133","primary_entity_name":"TANDEM DIABETES CARE INC"},"word_count":147,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAt the Annual Meeting, the Company’s stockholders also approved the Company’s 2023 Long-Term Incentive Plan, as amended, to, among other things, increase the number of shares of the Company’s common stock (Common Stock) authorized for issuance under the plan by 3,260,000 shares (as so amended, the Amended Plan). The Amended Plan was previously approved by the Board, subject to stockholder approval at the Annual Meeting. A description of the Amended Plan is set forth in the Proxy Statement in the section titled “Proposal 3: 2023 Long-Term Incentive Plan.”\n\nThe description of the Amended Plan contained herein and in the Proxy Statement are qualified in their entirety by reference to the Amended Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference."}